Clinical trials: Unresectable Pancreatic Carcinoma
Metastatic Pancreatic Ductal Adenocarcinoma, Stage III Pancreatic Cancer AJCC v8
CA-4948 Added to Standard Chemotherapy to Treat Metastatic or Unresectable Pancreatic Cancer
This phase I trial tests the safety, side effects, and best dose of emavusertib (CA-4948) in combination with gemcitabine and nab-paclitaxel in treating patients with pancreatic ductal adenocarcinoma that has spread from where it…
- Conditions
- Metastatic Pancreatic Ductal Adenocarcinoma, Stage III Pancreatic Cancer AJCC v8, Stage IV Pancreatic Cancer AJCC v8, Unresectable Pancreatic Ductal Adenocarcinoma
- Trial name
- NCT05685602
- Testing
- Biopsy Procedure, Biospecimen Collection, Computed Tomography
- Where
- 26 sites in United States
- Volunteers
- 43 people
- Sponsor
- National Cancer Institute (NCI)
Unresectable Pancreatic Cancer
MR Guided Phase II Radiotherapy Dose Escalation in Unresectable Non-Metastatic Pancreatic Cancer
This research study is for people who have pancreas cancer for which surgery is not recommended. Potential patients must have already received several months of chemotherapy before they are eligible for this study and there will…
- Trial name
- NCT01972919
- Testing
- Radiation Therapy, Concurrent chemotherapy (Gemcitabine, Capecitabine)
- Where
- United States
- Volunteers
- 23 people
- Sponsor
- Medical College of Wisconsin
Advanced Pancreatic Ductal Adenocarcinoma, Stage II Pancreatic Cancer AJCC v8
Lenvatinib and Pembrolizumab Maintenance Therapy for the Treatment of Patients of Advanced Unresectable Pancreatic Cancer
This phase II trial studies the effects of lenvatinib and pembrolizumab maintenance therapy in treating patients with pancreatic cancer that has spread to other places in the body (advanced) and cannot be removed by surgery…
- Conditions
- Advanced Pancreatic Ductal Adenocarcinoma, Stage II Pancreatic Cancer AJCC v8, Stage IIA Pancreatic Cancer AJCC v8, Stage IIB Pancreatic Cancer AJCC v8
- Trial name
- NCT04887805
- Testing
- Lenvatinib Mesylate, Pembrolizumab
- Where
- United States
- Volunteers
- 28 people
- Sponsor
- City of Hope Medical Center
Pancreatic Adenocarcinoma
Pancreatic Resectability in Cancers With Known Limited Extension (PRICKLE)
Pancreatic cancer is difficult to treat, and even in a situation where an operation can be performed to remove the cancer, the disease can unfortunately come back soon afterwards.
- Trial name
- PRICKLE (NCT02124369)
- Testing
- Abraxane, Gemcitabine
- Where
- United Kingdom
- Volunteers
- 9 people
- Sponsor
- CCTU- Cancer Theme
Pancreatic Adenocarcinoma
Pressure Enabled Drug Delivery By Pancreatic Retrograde Venous Infusion For Advanced Pancreatic Carcinoma
This is an open label, single institution, dose-escalation phase 1 study designed to assess the feasibility, safety, and efficacy of oxaliplatin administered via Pancreatic Retrograde Venous Infusion (PRVI) using Pressure Enabled…
- Trial name
- PANC-001 (NCT04270929)
- Testing
- FOLFIRI, FOLFIRINOX, TriSalus Infusion System
- Where
- United States
- Sponsor
- Roger Williams Medical Center
Stage III Pancreatic Cancer
A Registry Study of NanoKnife IRE for Stage 3 Pancreatic Cancer
This multicenter, observational study will evaluate the effectiveness and safety of the NanoKnife System when used for the ablation of Stage 3 pancreatic adenocarcinoma (Stage 3 PC).
- Trial name
- DIRECT (NCT03899649)
- Testing
- SOC, NanoKnife System
- Where
- 14 sites in United States
- Volunteers
- 532 people
- Sponsor
- Angiodynamics, Inc.
Pancreatic Cancer
Pancreatic Enzyme Supplementation in Patients With Unresectable Pancreatic Cancer (PESUP)
The investigators planned a prospective, randomized, placebo controlled trial to test the hypothesis that weight loss in patients with unresectable pancreatic cancer with occlusion of the pancreatic duct can be reduced or…
- Trial name
- NCT01587534
- Testing
- Norzyme
- Where
- South Korea
- Volunteers
- 67 people
- Sponsor
- National Cancer Center, Korea
Pancreatic Cancer
Phase I/II Intratumoral DC Immunotherapy With Gemcitabine & XRT in Unresectable Pancreatic Cancer
To determine the safety, feasibility and appropriate dendritic cell dose to vaccinate patients with pancreas cancer
- Trial name
- NCT00547144
- Testing
- Gemcitabine, Dendritic Cell Immunotherapy
- Where
- United States
- Volunteers
- 2 people
- Sponsor
- George Albert Fisher
Pancreatic Cancer, Pancreatic Cancer Non-resectable
RP72 Monotherapy and in Combination With Gemcitabine in Patients With Pancreatic Cancer
This is a Phase I, multi center study to evaluate the safety and efficacy and determine the maximum tolerated dose (MTD) of RP72 as monotherapy and RP72 in combination with Gemcitabine in patients with pancreatic cancer.
- Conditions
- Pancreatic Cancer, Pancreatic Cancer Non-resectable, Pancreatic Cancer Metastatic
- Trial name
- NCT04338763
- Testing
- RP72, Gemcitabine
- Where
- 2 sites in Taiwan
- Volunteers
- 48 people
- Sponsor
- Rise Biopharmaceuticals, Inc.
Extrahepatic Bile Duct Cancer, Gallbladder Cancer
Radiation Therapy in Treating Patients With Bile Duct, Gallbladder, or Pancreatic Cancer
RATIONALE: Radiation therapy uses high-energy x-rays to damage tumor cells. Motexafin gadolinium may increase the effectiveness of radiation therapy by making tumor cells more sensitive to treatment.
- Conditions
- Extrahepatic Bile Duct Cancer, Gallbladder Cancer, Pancreatic Cancer
- Trial name
- NCT00003411
- Testing
- motexafin gadolinium, radiation therapy
- Where
- 3 sites in United States
- Sponsor
- University of Pittsburgh
Solid Tumors, Neoplasms (Cancer / Tumors)
Exploratory Study on the Efficacy and Safety of Trastuzumab Rezetecan in the Treatment of HER2-Expressiong Advanced Solid Tumor
The goal of this clinical trial is to learn if Trastuzumab Rezetecan can treat advanced solid tumors with HER-2 expression in adult participants.
- Conditions
- Solid Tumors, Neoplasms (Cancer / Tumors), Advanced Malignant Solid Neoplasm, Locally Advanced Malignant Solid Neoplasm
- Trial name
- NCT07631884
- Testing
- Trastuzumab Rezetecan
- Volunteers
- 15 people
- Sponsor
- Haihua Yuan
Cancer
Aminocamptothecin in Treating Patients With Advanced Cancer of the Peritoneal Cavity
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: Phase I trial to study the effectiveness of aminocamptothecin in treating patients with advanced…
- Trial name
- NCT00003548
- Testing
- aminocamptothecin colloidal dispersion
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- NYU Langone Health
Adenocarcinoma of the Pancreas, Recurrent Pancreatic Cancer
UCN-01 and Gemcitabine in Treating Patients With Unresectable or Metastatic Pancreatic Cancer
Phase I trial to study the effectiveness of combining UCN-01 with gemcitabine in treating patients who have unresectable or metastatic pancreatic cancer.
- Conditions
- Adenocarcinoma of the Pancreas, Recurrent Pancreatic Cancer, Stage II Pancreatic Cancer, Stage III Pancreatic Cancer
- Trial name
- NCT00039403
- Testing
- 7-hydroxystaurosporine, gemcitabine hydrochloride, pharmacological study
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- National Cancer Institute (NCI)
Advanced Solid Tumors
Safety and Efficacy Study of PRI-724 in Subjects With Advanced Solid Tumors
PRI-724 is a new investigational drug being studied to treat subjects with cancer who have advanced solid tumors. PRI-724 is thought to work by blocking the Wnt signaling pathway that cancer cells need to grow and…
- Trial name
- NCT01302405
- Testing
- PRI-724
- Where
- 3 sites in United States
- Volunteers
- 23 people
- Sponsor
- Prism Pharma Co., Ltd.
Pancreatic Cancer Non-resectable
Safety and Performance of a Novel Infusion Catheter System for Peri/Intratumoral Gemcitabine Delivery in Patients With Pancreatic Cancer
This study is testing a new way to deliver the chemotherapy drug Gemcitabine in pancreatic tumors using the catheter Extroducer® Infusion Catheter System.
- Trial name
- NCT07575191
- Testing
- Gemcitabine, Extroducer Infusion Catheter System
- Where
- Sweden
- Volunteers
- 9 people
- Sponsor
- Smartwise Sweden AB
Mesothelin-Expressing Tumors, Epithelial Ovarian Cancer
CT-95 in Advanced Cancers Associated With Mesothelin Expression
This is a Phase 1a/1b, first-in-human (FIH), open-label, multi-center dose escalation and expansion study of the safety, pharmacokinetics (PK), pharmacodynamics, and antitumor activity of single-agent CT-95 in subjects with…
- Conditions
- Mesothelin-Expressing Tumors, Epithelial Ovarian Cancer, Malignant Pleural Mesothelioma, Advanced, Malignant Peritoneal Mesothelioma, Advanced
- Trial name
- NCT06756035
- Testing
- CT-95
- Where
- 9 sites in United States
- Volunteers
- 70 people
- Sponsor
- Context Therapeutics Inc.
Pancreatic Neoplasms
Phase 1/2a DTA-H19 in Patients With Unresectable Pancreatic Cancer
This study is designed to assess the safety, tolerability, pharmacokinetics (PK) and preliminary efficacy of DTA-H19 administered intratumorally in patients with unresectable, locally advanced pancreatic cancer.
- Trial name
- NCT00711997
- Testing
- DTA-H19
- Where
- 4 sites in United States, Israel
- Volunteers
- 9 people
- Sponsor
- Anchiano Therapeutics Israel Ltd.
Metastatic Lung Small Cell Carcinoma, Metastatic Malignant Solid Neoplasm
Testing the Addition of an Anti-cancer Drug, BAY 1895344, to Usual Chemotherapy for Advanced Stage Solid Tumors, With a Specific Focus on Patients With Small Cell Lung Cancer, Poorly Differentiated Neuroendocrine Cancer, and Pancreatic Cancer
This phase I trial tests the safety, side effects and best dose of BAY 1895344 when given together with usual chemotherapy (irinotecan or topotecan) in treating patients with solid tumors that may have spread from where it first…
- Conditions
- Metastatic Lung Small Cell Carcinoma, Metastatic Malignant Solid Neoplasm, Metastatic Neuroendocrine Carcinoma, Metastatic Pancreatic Adenocarcinoma
- Trial name
- NCT04514497
- Testing
- Biopsy Procedure, Biospecimen Collection, Computed Tomography
- Where
- 23 sites in United States
- Volunteers
- 29 people
- Sponsor
- National Cancer Institute (NCI)
Adenocarcinoma of the Pancreas, Pancreatic Cancer
Eribulin Mesylate as Second-Line Therapy for Locally Advanced, Unresectable, or Metastatic Pancreatic Cancer Patients
This phase II trial is studying how well E7389 works as second-line therapy in treating patients with locally advanced, unresectable, or metastatic pancreatic cancer.
- Conditions
- Adenocarcinoma of the Pancreas, Pancreatic Cancer, Recurrent Pancreatic Cancer, Stage II Pancreatic Cancer
- Trial name
- NCT00383760
- Testing
- eribulin mesylate
- Where
- Canada
- Volunteers
- 15 people
- Sponsor
- National Cancer Institute (NCI)
Non-metastasized Unresectable Pancreatic Carcinoma
Stereotactic Body Radiation Therapy for Inoperable Non-metastasized Pancreatic Adenocarcinoma
This is a multicenter randomized phase II trial that aims to include 160 patients with a non-metastatic (localized), inoperable pancreatic tumor. The study will take place at multiple centers across Europe.
- Trial name
- TORPEDO (NCT06691425)
- Testing
- Stereotactic Body Radiation Therapy (SBRT), Chemotherapy
- Where
- 9 sites in Belgium
- Volunteers
- 160 people
- Sponsor
- Cancer Research Antwerp